Анализ акций GLENMARK.NS
GL
Нет оценки
Количественный анализ Eyestock не покрывает акции Glenmark Pharmaceuticals Ltd.
Рейтинг
Для оценки качества бизнеса компании мы собрали все финансовые данные из отчетов и представили их в виде одного числа - рейтинга компании. Значение рейтинга 100 является пороговым для определения актуальной инвестиционной идеи.
Низкий рейтинг
Капитализация млрд. $
2.215
Дивидендная доходность
0.29 %
Оборот
282.19 млрд
Сайт компании
https://glenmarkpharma.com/Glenmark Pharmaceuticals Ltd. is a holding company, which engages in the development, manufacture and marketing of pharmaceutical products. The company is headquartered in Mumbai, Maharashtra and currently employs 15,556 full-time employees. The firm is focused on building a global formulation business with branded, generics and over the counter (OTC) segments in the therapy areas of dermatology, respiratory and oncology. The firm also has a regional/country-specific presence in other therapeutic areas like diabetes, cardiovascular and oral contraceptives. Its product portfolio includes topical products, liquids, respiratory MDI/DPI, complex injectables and biologics, and oral solids. The firm has a bioequivalent version of Tiotropium Bromide dry powder inhaler (DPI) under the brand, Tiogiva in the United Kingdom and Tavulus in Spain, for the treatment of chronic obstructive pulmonary disease. Ryaltris, the Company's first branded specialty product globally, is a fixed dose combination nasal spray that combines an antihistamine (Olopatadine) with a steroid (Mometasone Furoate) for treatment of allergic rhinitis.